Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Teva Pharmaceutical Industries : Secures Japanese Approval for Ajovy Injection as Preventive Migraine Treatment

06/23/2021 | 08:49am EDT


ę MT Newswires 2021
All news about TEVA PHARMACEUTICAL INDUSTRIES LIMITED
09/09TEVA PHARMACEUTICAL INDUSTRIES : - Late-Breaking Data at the International Heada..
AQ
09/09IMMUNEERING CORP : Results of Operations and Financial Condition, Financial Stat..
AQ
09/08TEVA PHARMACEUTICAL INDUSTRIES : Late-Breaking Data at the International Headach..
BU
09/02IMMUNEERING : to Participate in September Investor Conferences
AQ
09/01GLOBAL MARKETS LIVE : Getlink, Intuit, CrowdStrike, Xiaomi, Merck...
09/01Health Care Stocks Inch Higher Ahead of Wednesday Open
MT
09/01MEDINCELL S A : Teva Eye US Launch Of Schizophrenia Therapy In 2022
MT
09/01TEVA PHARMACEUTICAL INDUSTRIES : MedinCell Schizophrenia Therapy Accepted For Re..
MT
08/31TEVA PHARMACEUTICAL INDUSTRIES : Says FDA Accepts New Drug Application For Poten..
MT
08/31Teva, MedinCell Say FDA Accepts NDA for Schizophrenia Treatment
DJ
More news
Analyst Recommendations on TEVA PHARMACEUTICAL INDUSTRIES LIMITED
More recommendations
Financials (USD)
Sales 2021 16 294 M - -
Net income 2021 1 074 M - -
Net Debt 2021 21 871 M - -
P/E ratio 2021 11,4x
Yield 2021 -
Capitalization 9 915 M 9 915 M -
EV / Sales 2021 1,95x
EV / Sales 2022 1,80x
Nbr of Employees 37 736
Free-Float 90,3%
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | TEVA | US8816242098 | MarketScreener
Technical analysis trends TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 8,99 $
Average target price 12,04 $
Spread / Average Target 33,9%
EPS Revisions
Managers and Directors
Kňre Schultz President, Chief Executive Officer & Director
Eli Kalif Chief Financial Officer & Executive Vice President
Sol J. Barer Chairman
Hafrun Fridriksdottir Executive VP-Global Research & Development
Eric DrapÚ Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-6.84%9 915
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604